

Neurofibromatosis Type 2 Market 2026

<https://marketpublishers.com/r/ND16A4CCFC3DEN.html>

Date: April 2026

Pages: 218

Price: US\$ 2,999.00 (Single User License)

ID: ND16A4CCFC3DEN

Abstracts

The Neurofibromatosis Type 2 Market was valued at in and is anticipated to reach by , at a CAGR of xx% from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Neurofibromatosis Type 2 Market.

This report delivers a comprehensive overview of the Neurofibromatosis Type 2 Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Neurofibromatosis Type 2 Market. The Neurofibromatosis Type 2 Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for –.

Neurofibromatosis Type 2 Market Scope:

By Treatment Type

Surgery

Radiation Therapy

Drug Therapy

Others

By End-User

Hospitals

Cancer Centers

Others

Key Players

Manus Aktteva Biopharma LLP

AstraZeneca Plc

OCEAN PHARMACEUTICAL

Vivace Therapeutics

Ikena Oncology, Inc.

Recursion Pharmaceuticals Inc.

Major Highlights

This report delivers a comprehensive overview of the Neurofibromatosis Type 2 Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Neurofibromatosis Type 2 Market. The Neurofibromatosis Type 2 Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for –.

This report will assist keyword manufacturers, new entrants, and companies across the

industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Regional Analysis:

North America (U.S., Canada, Mexico)

Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

South America (Colombia, Brazil, Argentina, Rest of South America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Partner Identification

Increase Your Customer Base by 3X using our Partner Identification tool

Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.

Identify high potential M&A targets based on synergies, market positioning and growth trajectory.

Prioritize partners by strategic fit rather than general capability.

Why Choose DataM?

Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.

Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.

White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.

Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.

Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.

Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

Target Audience 2026

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

Contents

1. METHODOLOGY AND SCOPE

- 1.1. Research Methodology
- 1.2. Research Objective and Scope of the Report

2. DEFINITION AND OVERVIEW

3. EXECUTIVE SUMMARY

- 3.1. Snippet by Tumor Type
- 3.2. Snippet by Treatment Type
- 3.3. Snippet by End-User
- 3.4. Snippet by Region

4. DYNAMICS

- 4.1. Impacting Factors
 - 4.1.1. Drivers
 - 4.1.1.1. Rise in research and developmental activities
 - 4.1.1.2. XX
 - 4.1.2. Restraints
 - 4.1.2.1. Lack of drug approvals and fewer treatment options
 - 4.1.3. Opportunity
 - 4.1.4. Impact Analysis

5. INDUSTRY ANALYSIS

- 5.1. Porter's Five Force Analysis
- 5.2. Supply Chain Analysis
- 5.3. Epidemiology Statistics
- 5.4. Pricing Analysis
- 5.5. Regulatory Analysis
- 5.6. Russia-Ukraine War Impact Analysis
- 5.7. DMI Opinion

6. TUMOR TYPE

6.1. Introduction

6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Tumor Type

6.1.2. Market Attractiveness Index, By Tumor Type

6.2. Vestibular Schwannomas

6.2.1. Introduction

6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

6.3. Meningiomas

6.4. Other Tumors

7. BY TREATMENT TYPE

7.1. Introduction

7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type

7.1.2. Market Attractiveness Index, By Treatment Type

7.2. Surgery

7.2.1. Introduction

7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

7.2.3. Tumor Removal

7.2.4. Stereotactic Radiosurgery

7.2.5. Others

7.3. Radiation Therapy

7.4. Drug Therapy

7.4.1. Lapatinib

7.4.2. Selumetinib

7.4.3. Bevacizumab

7.4.4. Others

7.5. Others

8. BY END-USER

8.1. Introduction

8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

8.1.2. Market Attractiveness Index, By End-User

8.2. Hospitals

8.2.1. Introduction

8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

8.3. Cancer Centers

8.4. Others

9. BY REGION

9.1. Introduction

9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region

9.1.2. Market Attractiveness Index, By Region

9.2. North America

9.2.1. Introduction

9.2.2. Key Region-Specific Dynamics

9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Tumor Type

9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type

9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

9.2.6.1. U.S.

9.2.6.2. Canada

9.2.6.3. Mexico

9.3. Europe

9.3.1. Introduction

9.3.2. Key Region-Specific Dynamics

9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Tumor Type

9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type

9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

9.3.6.1. Germany

9.3.6.2. UK

9.3.6.3. France

9.3.6.4. Italy

9.3.6.5. Spain

9.3.6.6. Rest of Europe

9.4. South America

9.4.1. Introduction

9.4.2. Key Region-Specific Dynamics

9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Tumor Type

9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type

9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

9.4.6.1. Brazil

9.4.6.2. Argentina

9.4.6.3. Rest of South America

9.5. Asia-Pacific

- 9.5.1. Introduction
- 9.5.2. Key Region-Specific Dynamics
- 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Tumor Type
- 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
- 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
 - 9.5.6.1. China
 - 9.5.6.2. India
 - 9.5.6.3. Japan
 - 9.5.6.4. Australia
 - 9.5.6.5. Rest of Asia-Pacific

9.6. Middle East and Africa

- 9.6.1. Introduction
- 9.6.2. Key Region-Specific Dynamics
- 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Tumor Type
- 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
- 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

10. COMPETITIVE LANDSCAPE

- 10.1. Competitive Scenario
- 10.2. Market Positioning/Share Analysis
- 10.3. Mergers and Acquisitions Analysis

11. COMPANY PROFILES

- 11.1. Manus Aktteva Biopharma LLP*
 - 11.1.1. Company Overview
 - 11.1.2. Product Portfolio and Description
 - 11.1.3. Financial Overview
 - 11.1.4. Key Developments
- 11.2. AstraZeneca Plc
- 11.3. OCEAN PHARMACEUTICAL
- 11.4. Vivace Therapeutics
- 11.5. Ikena Oncology, Inc.
- 11.6. Recursion Pharmaceuticals Inc. (*LIST NOT EXHAUSTIVE)

12. APPENDIX

12.1. About Us and Services

12.2. Contact Us

I would like to order

Product name: Neurofibromatosis Type 2 Market 2026

Product link: <https://marketpublishers.com/r/ND16A4CCFC3DEN.html>

Price: US\$ 2,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/ND16A4CCFC3DEN.html>